117 related articles for article (PubMed ID: 37003861)
1. Estimating the Effectiveness of Kidney Cancer Screening Within Lung Cancer Screening Programmes: A Validation in UK Biobank.
Harrison H; Wood A; Pennells L; Rossi SH; Callister M; Cartledge J; Stewart GD; Usher-Smith JA
Eur Urol Oncol; 2023 Jun; 6(3):351-353. PubMed ID: 37003861
[TBL] [Abstract][Full Text] [Related]
2. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
3. The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer.
Usher-Smith JA; Godoy A; Burge SW; Burbidge S; Cartledge J; Crosbie PAJ; Eckert C; Farquhar F; Hammond D; Hancock N; Iball GR; Kimuli M; Masson G; Neal RD; Rogerson S; Rossi SH; Sala E; Smith A; Sharp SJ; Simmonds I; Wallace T; Ward M; Callister MEJ; Stewart GD
BMJ Open; 2022 Sep; 12(9):e063018. PubMed ID: 36127097
[TBL] [Abstract][Full Text] [Related]
4. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
[TBL] [Abstract][Full Text] [Related]
5. Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven other risk prediction models.
Liao W; Coupland CAC; Burchardt J; Baldwin DR; ; Gleeson FV; Hippisley-Cox J
Lancet Respir Med; 2023 Aug; 11(8):685-697. PubMed ID: 37030308
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
[TBL] [Abstract][Full Text] [Related]
7. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom.
Robbins HA; Alcala K; Swerdlow AJ; Schoemaker MJ; Wareham N; Travis RC; Crosbie PAJ; Callister M; Baldwin DR; Landy R; Johansson M
Br J Cancer; 2021 Jun; 124(12):2026-2034. PubMed ID: 33846525
[TBL] [Abstract][Full Text] [Related]
8. Validation and public health modelling of risk prediction models for kidney cancer using the UK Biobank.
Harrison H; Pennells L; Wood A; Rossi SH; Stewart GD; Griffin SJ; Usher-Smith JA
BJU Int; 2022 Apr; 129(4):498-511. PubMed ID: 34538014
[TBL] [Abstract][Full Text] [Related]
9. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.
Li K; Hüsing A; Sookthai D; Bergmann M; Boeing H; Becker N; Kaaks R
Cancer Prev Res (Phila); 2015 Sep; 8(9):777-85. PubMed ID: 26076698
[TBL] [Abstract][Full Text] [Related]
10. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
11. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
12. [Construction of a Risk Prediction Model for Lung Cancer Based on Lifestyle Behaviors in the UK Biobank Large-Scale Population Cohort].
Chen R; Wang J; Wang S; Tang S; Suo C
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 54(5):892-898. PubMed ID: 37866943
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Selection criteria for lung-cancer screening.
Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
[TBL] [Abstract][Full Text] [Related]
15. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
[TBL] [Abstract][Full Text] [Related]
16. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening.
Field JK; Duffy SW; Baldwin DR; Whynes DK; Devaraj A; Brain KE; Eisen T; Gosney J; Green BA; Holemans JA; Kavanagh T; Kerr KM; Ledson M; Lifford KJ; McRonald FE; Nair A; Page RD; Parmar MK; Rassl DM; Rintoul RC; Screaton NJ; Wald NJ; Weller D; Williamson PR; Yadegarfar G; Hansell DM
Thorax; 2016 Feb; 71(2):161-70. PubMed ID: 26645413
[TBL] [Abstract][Full Text] [Related]
17. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening.
McRonald FE; Yadegarfar G; Baldwin DR; Devaraj A; Brain KE; Eisen T; Holemans JA; Ledson M; Screaton N; Rintoul RC; Hands CJ; Lifford K; Whynes D; Kerr KM; Page R; Parmar M; Wald N; Weller D; Williamson PR; Myles J; Hansell DM; Duffy SW; Field JK
Cancer Prev Res (Phila); 2014 Mar; 7(3):362-71. PubMed ID: 24441672
[TBL] [Abstract][Full Text] [Related]
18. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
19. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
Hüsing A; Kaaks R
Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.
Black C; Bagust A; Boland A; Walker S; McLeod C; De Verteuil R; Ayres J; Bain L; Thomas S; Godden D; Waugh N
Health Technol Assess; 2006 Jan; 10(3):iii-iv, ix-x, 1-90. PubMed ID: 16409881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
